Literature DB >> 2386202

Vascular effects of cyclosporine A in vivo and in vitro.

G Ferns1, M Reidy, R Ross.   

Abstract

The authors have evaluated the in vivo effects of cyclosporine A on the de-endothelialized rabbit carotid artery. Vascular endothelium was gently removed from the common carotid artery of 10 New Zealand White rabbits that then were treated with therapeutic doses of cyclosporine A (15 mg/kg/day), or its vehicle (Cremophor-EL). Significant intimal proliferation was observed in all cases 2 weeks after de-endothelialization. Concomitant cyclosporine A therapy had no significant effect on intimal smooth muscle proliferation, but was associated with 1) intimal smooth muscle vacuolation, 2) an increase in total intimal thickening, because of the presence of numerous macrophage-derived foam cells, and 3) incorporation of 3H-thymidine by neo-intimal monocyte/macrophages. Mean plasma cholesterol levels were moderately increased in both groups. Although this may have contributed to foam cell formation in the cyclosporine-A-treated animals, it was not the sole determinant, as foam-cell-rich lesions were not observed in control animals. In vitro, cyclosporine A reduced the rate of proliferation of rabbit aortic smooth muscle and endothelial cells in a dose-dependent fashion, and induced smooth muscle cell vacuolation. These data suggest that cyclosporine A may contribute to the formation of graft-related atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386202      PMCID: PMC1877614     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

Authors:  K P Harris; G I Russell; S D Parvin; P S Veitch; J Walls
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography.

Authors:  G C Kahn; L M Shaw; M D Kane
Journal:  J Anal Toxicol       Date:  1986 Jan-Feb       Impact factor: 3.367

Review 3.  Cyclosporine: toxicity, metabolism, and drug interactions--implications from animal studies.

Authors:  P H Whiting; A W Thomson; J G Simpson
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

4.  Accelerated atherosclerosis in a cardiac transplant patient.

Authors:  R S Nitkin; S A Hunt; J S Schroeder
Journal:  J Am Coll Cardiol       Date:  1985-07       Impact factor: 24.094

5.  Cyclosporine toxicity in rabbits.

Authors:  A Gratwohl; I Riederer; E Graf; B Speck
Journal:  Lab Anim       Date:  1986-07       Impact factor: 2.471

6.  Cyclosporin-induced endothelial cell injury.

Authors:  C Zoja; L Furci; F Ghilardi; P Zilio; A Benigni; G Remuzzi
Journal:  Lab Invest       Date:  1986-10       Impact factor: 5.662

7.  Fatty streak initiation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits.

Authors:  M E Rosenfeld; T Tsukada; A M Gown; R Ross
Journal:  Arteriosclerosis       Date:  1987 Jan-Feb

8.  Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit.

Authors:  T Tsukada; M Rosenfeld; R Ross; A M Gown
Journal:  Arteriosclerosis       Date:  1986 Nov-Dec

9.  Effects of cyclosporin A on a kidney epithelial cell line (LLC-PK1).

Authors:  G M Becker; A J Gandolfi; R B Nagle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-05

10.  Interaction of cyclosporin A with human lipoproteins.

Authors:  D Sgoutas; W MacMahon; A Love; I Jerkunica
Journal:  J Pharm Pharmacol       Date:  1986-08       Impact factor: 3.765

View more
  17 in total

1.  T lymphocytes inhibit the vascular response to injury.

Authors:  G K Hansson; J Holm; S Holm; Z Fotev; H J Hedrich; J Fingerle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

3.  Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia.

Authors:  M A Nugent; H M Nugent; R V Iozzo; K Sanchack; E R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absence of functional T lymphocytes.

Authors:  G A Ferns; M A Reidy; R Ross
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 5.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  The comparative role of 1,25-dihydroxycholecalciferol and phorbol esters in the differentiation of the U937 cell line.

Authors:  M Hewison; A Brennan; R Singh-Ranger; J C Walters; D R Katz; J L O'Riordan
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

7.  Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit.

Authors:  G A Ferns; L Forster; A Stewart-Lee; M Konneh; J Nourooz-Zadeh; E E Anggård
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

8.  Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection.

Authors:  S G Tullius; U Heemann; W W Hancock; H Azuma; N L Tilney
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

9.  Cyclosporine is angiostatic.

Authors:  K Norrby
Journal:  Experientia       Date:  1992-12-01

10.  Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity.

Authors:  S E Roselaar; G Schonfeld; A Daugherty
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.